What are the indications, techniques, and pre‑ and post‑procedural considerations for cardioversion in atrial fibrillation?

Cardioversion for Atrial Fibrillation

Direct Answer

For patients with atrial fibrillation requiring cardioversion, immediate electrical cardioversion is mandatory when hemodynamic instability is present (angina, MI, shock, pulmonary edema), while elective cardioversion requires 3 weeks of therapeutic anticoagulation beforehand and 4 weeks afterward, regardless of whether electrical or pharmacological methods are used. 1

---

Indications for Cardioversion

Immediate Cardioversion (Class I)

• Hemodynamic instability with ongoing myocardial ischemia, symptomatic hypotension, angina, or heart failure not responding to pharmacological rate control 1
• Pre-excitation syndromes (e.g., WPW) with very rapid ventricular rates or hemodynamic compromise 1
• First episode of AF or when symptoms are unacceptable to the patient despite adequate rate control 1

Elective Cardioversion (Class I/IIa)

• Part of long-term rhythm control strategy in symptomatic patients 1
• Repeated cardioversions are reasonable when sinus rhythm can be maintained for clinically meaningful periods between procedures 1

---

Anticoagulation Strategy: The Critical Decision Point

AF Duration ≥48 Hours or Unknown Duration

Standard approach (Class I):

• Therapeutic anticoagulation (INR 2.0-3.0 for warfarin, or therapeutic NOAC dosing) for at least 3 weeks before and 4 weeks after cardioversion 1
• This applies regardless of cardioversion method (electrical or pharmacological) 1
• NOACs (apixaban, rivaroxaban, dabigatran) are preferred over warfarin for peri-cardioversion anticoagulation 1

TEE-guided approach (Class IIa):

• If 3 weeks of anticoagulation has not been provided, perform TEE to exclude left atrial/LAA thrombus 1
• If no thrombus identified: initiate IV heparin or LMWH immediately, proceed with cardioversion, then continue oral anticoagulation for at least 4 weeks 1
• If thrombus present: anticoagulate for at least 3-4 weeks, repeat TEE, then cardiovert if resolved 1

AF Duration <48 Hours

High stroke risk (CHADS₂-VASc ≥2 in men, ≥3 in women) (Class IIa):

• Administer heparin, factor Xa inhibitor, or direct thrombin inhibitor before cardioversion, followed by long-term anticoagulation based on stroke risk 1

Low stroke risk (CHADS₂-VASc 0 in men, 1 in women) (Class IIb):

• Anticoagulation may be considered but is not mandatory for cardioversion itself 1
• However, recent data shows thromboembolic events can occur even with AF <48 hours, particularly in patients with risk factors 1

Hemodynamically Unstable AF Requiring Immediate Cardioversion

Do not delay for anticoagulation (Class I):

• Cardiovert immediately 1
• Initiate IV heparin bolus followed by continuous infusion (aPTT 1.5-2× control) or LMWH concurrently unless contraindicated 1
• Continue oral anticoagulation (INR 2.0-3.0) for at least 4 weeks post-cardioversion 1

Post-Cardioversion Anticoagulation Duration

Long-term anticoagulation decision should be based on thromboembolic risk profile (CHADS₂-VASc score) and bleeding risk, NOT on whether sinus rhythm is maintained 1. This is critical because:

• Atrial mechanical stunning occurs after cardioversion, with delayed recovery of atrial contraction 1
• 98% of thromboembolic events occur within 10 days post-cardioversion 1
• AF recurrence risk remains high regardless of immediate post-cardioversion rhythm 1

---

Electrical Cardioversion Technique

Optimal Technical Approach (Class I)

• R-wave synchronized direct-current shock 1
• Biphasic waveforms are more effective than monophasic 2
• Initial energy: 200 joules for monophasic; biphasic devices may start lower 1, 3
• Electrode placement: Anterior-posterior position superior to anterior-lateral (one electrode anterior, second below left scapula) 3
• Electrode size: At least 8 cm diameter anteriorly, 12-13 cm posteriorly 3
• Patient in expiration to decrease anterior-posterior chest diameter 3

Contraindications (Class III)

• Digitalis toxicity 1
• Hypokalemia 1
• Do not perform frequent repeated cardioversions in patients with short sinus rhythm periods despite antiarrhythmic therapy 1

Enhancing Success (Class IIa)

• Pretreatment with antiarrhythmics (amiodarone, flecainide, ibutilide, propafenone, or sotalol) can enhance success and prevent early recurrence 1
• If initial cardioversion fails, repeat after antiarrhythmic loading 1

---

Pharmacological Cardioversion

First-Line Agents (Class I)

For patients WITHOUT structural heart disease, LV dysfunction, or CAD:

• Flecainide (Class IC): IV or oral dosing 1
• Propafenone (Class IC): IV or oral dosing 1
• Ibutilide (Class III): IV administration 1
• Vernakalant (Class III): IV administration, excluding recent ACS, HFrEF, or severe aortic stenosis 1

For patients WITH structural heart disease, LVH, HFrEF, or CAD:

• Amiodarone (Class III): IV or oral, though cardioversion may be delayed 1
• Amiodarone is reasonable for outpatient use when rapid restoration is not necessary 1

"Pill-in-the-Pocket" Approach (Class IIa)

• Single oral dose of propafenone or flecainide for out-of-hospital termination of AF 1
• Requires: Prior in-hospital safety verification, absence of sinus/AV node dysfunction, no bundle branch block, no QT prolongation, no Brugada syndrome, no structural heart disease 1
• Must pretreat with beta-blocker or non-dihydropyridine calcium channel blocker to prevent rapid AV conduction if atrial flutter occurs 1

Agents to Avoid (Class III)

Digoxin and sotalol may be harmful for acute pharmacological cardioversion 1

Contraindications for Pharmacological Cardioversion (Class III)

• Sinus node dysfunction 1
• AV conduction disturbances 1
• Prolonged QTc (>500 ms) 1
• Must exclude contraindications specific to each drug before use 1

---

Common Pitfalls and Caveats

Anticoagulation Errors

• Never withhold anticoagulation post-cardioversion based on maintenance of sinus rhythm—the decision is based on stroke risk factors, not rhythm 1
• Do not use the 48-hour rule as absolute—patients with AF <48 hours and high stroke risk still benefit from anticoagulation 1
• Atrial stunning persists for weeks after cardioversion, maintaining thrombotic risk even in sinus rhythm 1

Drug Selection Errors

• Never use flecainide or propafenone in patients with structural heart disease, CAD, LV dysfunction, or significant LVH—risk of proarrhythmia 1
• Avoid digoxin and non-dihydropyridine calcium channel blockers in pre-excitation syndromes (WPW)—they may accelerate ventricular response and cause ventricular fibrillation 1
• Do not initiate dofetilide outside hospital—requires in-hospital monitoring for QT prolongation 1

Procedural Errors

• Electrical cardioversion is contraindicated with digitalis toxicity—risk of ventricular arrhythmias 1
• Correct hypokalemia before cardioversion—increases defibrillation threshold and arrhythmia risk 1

Post-Cardioversion Bradycardia

• Anticipate bradycardia, especially in elderly patients with structural heart disease or those on AV nodal blocking agents 4
• Have atropine, temporary pacing capability, and vasopressors immediately available 4

---

Rate Control During Acute AF (Before Cardioversion Decision)

First-Line Agents (Class I)

• Beta-blockers (metoprolol, esmolol, propranolol) 1
• Non-dihydropyridine calcium channel blockers (diltiazem, verapamil) 1
• Digoxin (slower onset, useful in HF with reduced EF) 1

Target Heart Rate

• Strict control (<80 bpm resting) is reasonable for symptomatic management 1
• Lenient control (<110 bpm resting) may be reasonable if patients remain asymptomatic and LV function preserved 1

---

Algorithm for Clinical Decision-Making

Step 1: Assess hemodynamic stability

• Unstable (angina, MI, shock, pulmonary edema) → Immediate electrical cardioversion + concurrent heparin 1
• Stable → Proceed to Step 2

Step 2: Determine AF duration

• ≥48 hours or unknown → Requires 3 weeks anticoagulation OR TEE-guided approach 1
• <48 hours → Assess stroke risk (Step 3)

Step 3: For AF <48 hours, assess CHADS₂-VASc score

• Score ≥2 (men) or ≥3 (women) → Anticoagulate before cardioversion 1
• Score 0 (men) or 1 (women) → Anticoagulation optional for cardioversion itself 1

Step 4: Choose cardioversion method

• Electrical preferred for: persistent AF, atrial flutter, need for immediate rhythm restoration 1, 5, 6
• Pharmacological acceptable for: recent-onset AF, patient preference, no immediate urgency 1

Step 5: Select pharmacological agent (if chosen)

• No structural heart disease/CAD/LV dysfunction → Flecainide, propafenone, ibutilide, or vernakalant 1
• Structural heart disease/CAD/LV dysfunction → Amiodarone only 1

Step 6: Post-cardioversion management

• Continue anticoagulation for minimum 4 weeks 1
• Long-term anticoagulation based on CHADS₂-VASc score, NOT rhythm 1
• Consider antiarrhythmic therapy to maintain sinus rhythm if recurrence likely 1